- Home
- STRT vs IFRX Comparison
STRT vs IFRX Comparison
Compare STRT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRT
- IFRX
- Stock Information
- Founded
- STRT 1908
- IFRX 2007
- Country
- STRT United States
- IFRX Germany
- Employees
- STRT N/A
- IFRX N/A
- Industry
- STRT Auto Parts:O.E.M.
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- STRT Consumer Discretionary
- IFRX Health Care
- Exchange
- STRT Nasdaq
- IFRX Nasdaq
- Market Cap
- STRT N/A
- IFRX 65.8M
- IPO Year
- STRT 1995
- IFRX 2017
- Fundamental
- Price
- STRT $64.07
- IFRX $0.79
- Analyst Decision
- STRT
- IFRX Strong Buy
- Analyst Count
- STRT 0
- IFRX 4
- Target Price
- STRT N/A
- IFRX $7.75
- AVG Volume (30 Days)
- STRT 93.0K
- IFRX 346.2K
- Earning Date
- STRT 08-07-2025
- IFRX 08-07-2025
- Dividend Yield
- STRT N/A
- IFRX N/A
- EPS Growth
- STRT 395.63
- IFRX N/A
- EPS
- STRT 4.94
- IFRX N/A
- Revenue
- STRT $556,108,000.00
- IFRX $140,242.00
- Revenue This Year
- STRT $5.57
- IFRX N/A
- Revenue Next Year
- STRT $1.37
- IFRX $6,309.47
- P/E Ratio
- STRT $12.56
- IFRX N/A
- Revenue Growth
- STRT 5.54
- IFRX 30.90
- 52 Week Low
- STRT $21.05
- IFRX $0.71
- 52 Week High
- STRT $66.10
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- STRT 67.86
- IFRX 35.74
- Support Level
- STRT $55.35
- IFRX $0.77
- Resistance Level
- STRT $59.00
- IFRX $0.83
- Average True Range (ATR)
- STRT 2.82
- IFRX 0.05
- MACD
- STRT -0.48
- IFRX 0.02
- Stochastic Oscillator
- STRT 79.70
- IFRX 35.40
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.